Literature DB >> 10675404

Morphogenesis and release of fowlpox virus.

D Boulanger1, T Smith, M A Skinner.   

Abstract

Release of fowlpox virus (FWPV) as extracellular enveloped virus (EEV) appears to proceed both by the budding of intracellular mature virus (IMV) through the plasma membrane and by the fusion of intracellular enveloped virus (IEV) with the plasma membrane. Based on the frequency of budding events compared to wrapping events observed by electron microscopy, FWPV FP9 strain seems to exit chick embryo fibroblast cells predominantly by budding. In contrast to vaccinia virus (VV), the production of FWPV extracellular virus particles is not affected by N(1)-isonicotinoyl-N(2)-3-methyl-4-chlorobenzoylhydrazine (IMCBH). Comparison of the sequence of the VV F13L gene product with its FWPV orthologue showed a mutation, in the fowlpox protein, at the residue involved in IMCBH resistance in a mutant VV. Glucosamine, monensin or brefeldin A did not have any specific effect on FWPV extracellular virus production. Cytochalasin D, which inhibits the formation of actin filaments, reduces the production of extracellular virus particles by inhibiting the release of cell-associated enveloped virus (CEV) particles from the plasma membrane. Involvement of actin filaments in this mechanism is further supported by the co-localization of actin with viral particles close to the plasma membrane in the absence of cytochalasin D. Actin is also co-localized with virus factories.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675404     DOI: 10.1099/0022-1317-81-3-675

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

Review 1.  Poxvirus membrane biogenesis.

Authors:  Bernard Moss
Journal:  Virology       Date:  2015-02-26       Impact factor: 3.616

2.  Flow Cytometric Evaluation of CD4+ and CD8+ T-cell Immune Response in SPF Chickens Induced by Fowlpox Vaccine.

Authors:  M R Azizi; E Asli; A M Behroozikhah; B Khalesi
Journal:  Arch Razi Inst       Date:  2021-09-01

3.  Identification and characterization of three immunodominant structural proteins of fowlpox virus.

Authors:  Denise Boulanger; Philip Green; Brenda Jones; Gwenn Henriquet; Lawrence G Hunt; Stephen M Laidlaw; Paul Monaghan; Michael A Skinner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  The genome of canarypox virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells.

Authors:  Andrea Meiser; Carmen Sancho; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Vaccinia virus A36R membrane protein provides a direct link between intracellular enveloped virions and the microtubule motor kinesin.

Authors:  Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Interaction of poxvirus intracellular mature virion proteins with the TPR domain of kinesin light chain in live infected cells revealed by two-photon-induced fluorescence resonance energy transfer fluorescence lifetime imaging microscopy.

Authors:  Ananya Jeshtadi; Pierre Burgos; Christopher D Stubbs; Anthony W Parker; Linda A King; Michael A Skinner; Stanley W Botchway
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

8.  An efficient method for generating poxvirus recombinants in the absence of selection.

Authors:  Amanda D Rice; Stacey A Gray; Yu Li; Inger Damon; Richard W Moyer
Journal:  Viruses       Date:  2011-03       Impact factor: 5.048

Review 9.  Avipoxviruses: infection biology and their use as vaccine vectors.

Authors:  Simon C Weli; Morten Tryland
Journal:  Virol J       Date:  2011-02-03       Impact factor: 4.099

10.  Topographic changes in SARS coronavirus-infected cells at late stages of infection.

Authors:  M L Ng; J W M Lee; M L N Leong; A-E Ling; H-C Tan; E E Ooi
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.